Walleye Capital’s Arcutis Biotherapeutics ARQT Stock Holding History

Walleye Capital’s Portfolio ARQT Stock Details ARQT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.82M	Buy	260,033 +209,573	+415%	+$4.88M	0.02%	654
2026 Q1	$1.19M	Sell	50,460 -118,144	-70%	-$3.02M	﹤0.01%	1919
2025 Q4	$4.9M	Buy	168,604 +147,902	+714%	+$3.79M	0.02%	1165
2025 Q3	$390K	Sell	20,702 -4,227	-17%	-$66.7K	﹤0.01%	2806
2025 Q2	$350K	Buy	24,929 +24,210	+3,367%	+$339K	﹤0.01%	2935
2025 Q1	$11.2K	Buy	+719	New	+$10.1K	﹤0.01%	4058
2024 Q1	–	Sell	-323,600	Closed	-$1.05M	–	5397
2023 Q4	$1.05M	Buy	+323,600	New	+$880K	﹤0.01%	2303
2022 Q2	–	Sell	-75,553	Closed	-$1.46M	–	2341
2022 Q1	$1.46M	Sell	75,553 -7,867	-9%	-$133K	0.04%	468
2021 Q4	$1.73M	Buy	+83,420	New	+$1.66M	0.05%	365

Other funds holding ARQT

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Walleye Capital's ARQT Position: Q2 2026 in Review

Walleye Capital increased its Arcutis Biotherapeutics (ARQT) stake by 415% in Q2 2026, buying an estimated $4.88M and bringing the position to 260,033 shares worth $6.82M. The position accounts for 0.02% of the portfolio, ranked #654.

Walleye Capital first reported a position in ARQT in Q4 2021 and has held it in 9 quarters since. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

Walleye Capital held 260,033 shares of Arcutis Biotherapeutics worth $6.82M as of Q2 2026.
Walleye Capital bought 209,573 Arcutis Biotherapeutics shares in Q2 2026, an estimated $4.88M.
Arcutis Biotherapeutics made up 0.02% of Walleye Capital's portfolio in Q2 2026, its #654 holding.
Walleye Capital first reported a position in Arcutis Biotherapeutics in Q4 2021 and has held it in 9 quarters since.
272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.